Eli Lilly and Company (NYSE:LLY) Shares Purchased by Darden Wealth Group Inc

Darden Wealth Group Inc grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.8% in the third quarter, Holdings Channel.com reports. The fund owned 1,515 shares of the company’s stock after buying an additional 55 shares during the quarter. Eli Lilly and Company comprises about 1.0% of Darden Wealth Group Inc’s holdings, making the stock its 23rd biggest position. Darden Wealth Group Inc’s holdings in Eli Lilly and Company were worth $1,342,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of LLY. Westwood Holdings Group Inc. raised its stake in Eli Lilly and Company by 5.4% during the 1st quarter. Westwood Holdings Group Inc. now owns 3,839 shares of the company’s stock valued at $2,987,000 after purchasing an additional 196 shares during the period. Guardian Capital LP raised its position in Eli Lilly and Company by 3.0% during the first quarter. Guardian Capital LP now owns 921 shares of the company’s stock valued at $717,000 after buying an additional 27 shares during the period. Linscomb Wealth Inc. boosted its position in Eli Lilly and Company by 0.5% during the 1st quarter. Linscomb Wealth Inc. now owns 3,389 shares of the company’s stock worth $2,637,000 after acquiring an additional 17 shares during the period. Steel Grove Capital Advisors LLC lifted its position in shares of Eli Lilly and Company by 104.9% in the first quarter. Steel Grove Capital Advisors LLC now owns 795 shares of the company’s stock worth $618,000 after purchasing an additional 407 shares in the last quarter. Finally, Beck Capital Management LLC grew its position in Eli Lilly and Company by 1.9% during the first quarter. Beck Capital Management LLC now owns 8,824 shares of the company’s stock valued at $6,865,000 after purchasing an additional 163 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Sanford C. Bernstein began coverage on shares of Eli Lilly and Company in a research note on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 target price for the company. JPMorgan Chase & Co. boosted their target price on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Friday, September 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a research report on Monday, September 16th. Truist Financial increased their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a report on Thursday, October 10th. Finally, BMO Capital Markets boosted their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Four investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,007.94.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $748.91 on Friday. The firm has a market capitalization of $710.96 billion, a price-to-earnings ratio of 80.96, a PEG ratio of 2.76 and a beta of 0.43. Eli Lilly and Company has a one year low of $561.65 and a one year high of $972.53. The business has a fifty day simple moving average of $868.53 and a 200 day simple moving average of $869.14. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The business had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. Eli Lilly and Company’s revenue was up 20.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.10 earnings per share. Sell-side analysts expect that Eli Lilly and Company will post 13.21 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 annualized dividend and a yield of 0.69%. Eli Lilly and Company’s dividend payout ratio is currently 56.22%.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at $4,402,522.40. This represents a 14.11 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.